Table 4.

Cox regression: Hazard ratios across international targets of serum phosphate for CKD stages 3 to 5

	UK Renal Association				KDOQI
	All-Cause Mortality		CV Mortality		All-Cause Mortality		CV Mortality
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Below target	1.0		1.0		1.0		1.0
In target	1.7 (1.0, 2.8)	0.05	1.6 (0.8, 3.5)	0.2	1.8 (0.98, 3.8)	0.06	1.8 (0.7, 4.6)	0.2
Above target	2.8 (1.5, 5.4)	0.002	4.1 (1.5, 10.6)	0.004	2.7 (1.3, 5.7)	0.009	4.0 (1.4, 11.9)	0.01

UKRA target range: CKD stages 3 to 4: 0.9 to 1.5 mmol/L; CKD stage 5: 1.1 to 1.8 mmol/L. KDOQI target range: CKD stages 3 to 4: 0.87 to 1.48 mmol/L; CKD stage 5: 1.13 to 1.78 mmol/L. Analysis adjusted for age, gender, proteinuria, diabetes, hemoglobin, systolic blood pressure, current smoking status, cardiovascular disease, eGFR, and vitamin D analog and phosphate binder use.